US Patent

US7635773 — Sulfoalkyl ether cyclodextrin compositions

Formulation · Assigned to Cydex Pharmaceuticals Inc · Expires 2029-03-13 · 3y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects compositions of sulfoalkyl ether cyclodextrin and methods for making and using them, particularly in relation to a specific absorption measurement.

USPTO Abstract

SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD composition comprises a sulfoalkyl ether cyclodextrin and less than 100 ppm of a phosphate, wherein the SAE-CD composition has an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.

Drugs covered by this patent

Patent Metadata

Patent number
US7635773
Jurisdiction
US
Classification
Formulation
Expires
2029-03-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Cydex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.